Tonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia
Results from Planned Interim Analysis of First 50 Percent of Participants Expected Second Quarter 2023…
Instruct3D Strengthens Additive Build Intelligence Message Following ICAM 2026
Otto Group and Sereact Bring NVIDIA-Powered Physical AI to Returns Processing